Bioavailability and efficacy of omeprazole given orally and by nasogastric tube

被引:38
作者
Larson, C
Cavuto, NJ
Flockhart, DA
Weinberg, RB
机构
[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,GASTROENTEROL SECT,WINSTON SALEM,NC 27157
[2] MASSACHUSETTS GEN HOSP,DEPT PEDIAT,DIV GASTROENTEROL,BOSTON,MA 02114
[3] GEORGETOWN UNIV,MED CTR,DEPT MED,DIV CLIN PHARMACOL,WASHINGTON,DC 20007
[4] GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,DIV CLIN PHARMACOL,WASHINGTON,DC 20007
关键词
omeprazole; gastric acid secretion; nasogastric tube; pharmacokinetics; pentagastrin; cytochrome P-450; bioavailability;
D O I
10.1007/BF02282321
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We compared the bioavailability and the efficacy of omeprazole provided either as encapsulated enteric-coated granules or as enteric-coated granules delivered via a nasogastric tube in 10 healthy subjects. Omeprazole reduced mean pentagastrin-stimulated peak gastric acid secretion by 85.5% +/- 23.7% when delivered orally and by 79.6% +/- 32.1% when delivered by nasogastric tube; the mean plasma omeprazole concentration area under the curve (AUG) was 2.02 +/- 0.79 after oral delivery and 1.74 +/- 1.89 after nasogastric tube delivery. There was no significant difference in these parameters between the two routes of administration, and there was excellent intrasubject correlation between oral and nasogastric percent acid suppression and AUC. There was a close correlation between AUC and percent acid suppression at AUC values below 0.6, and complete acid suppression at AUC values above 0.6, regardless of the delivery route. We conclude that omeprazole delivered as enteric-coated granules via nasogastric tube provides equal bioavailability and gastric acid suppression as omeprazole given orally in its proprietary formulation.
引用
收藏
页码:475 / 479
页数:5
相关论文
共 23 条
[1]  
ADAMS MH, 1988, CLIN PHARMACY, V7, P725
[2]   PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
SKANBERG, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563
[3]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[4]  
ANDERSSON T, 1991, THESIS U GOTEBERG
[5]   THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].
BALIAN, JD ;
SUKHOVA, N ;
HARRIS, JW ;
HEWETT, J ;
PICKLE, L ;
GOLDSTEIN, JA ;
WOOSLEY, RL ;
FLOCKHART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669
[6]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[7]   INFLUENCE OF FOOD ON THE ABSORPTION OF ACETYLSALICYLIC-ACID FROM ENTERIC-COATED DOSAGE FORMS [J].
BOGENTOFT, C ;
CARLSSON, I ;
EKENVED, G ;
MAGNUSSON, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 14 (05) :351-355
[8]   EFFECT OF INTRAVENOUS AND ORAL OMEPRAZOLE ON 24-HOUR INTRAGASTRIC ACIDITY IN DUODENAL-ULCER PATIENTS [J].
CEDERBERG, C ;
THOMSON, ABR ;
MAHACHAI, V ;
WESTIN, JA ;
KIRDEIKIS, P ;
FISHER, D ;
ZUK, L ;
MARRIAGE, B .
GASTROENTEROLOGY, 1992, 103 (03) :913-918
[9]  
EARNEST DL, 1990, DICP ANN PHARMAC, V24, pS31
[10]   EFFECTS OF SINGLE AND REPEATED DOSES OF OMEPRAZOLE ON GASTRIC-ACID AND PEPSIN-SECRETION IN MAN [J].
HOWDEN, CW ;
FORREST, JAH ;
REID, JL .
GUT, 1984, 25 (07) :707-710